We are live on ! Find out more
BC

Birchview Capital Portfolio holdings

AUM $176M
1-Year Est. Return 95.04%
This Fund
S&P 500
This Quarter Est. Return
+4.03%
1 Year Est. Return
+95.04%
3 Year Est. Return
+233.14%
5 Year Est. Return
+280.2%
10 Year Est. Return
+1,023.63%
AUM
$155M
AUM Growth
+$8.11M
Cap. Flow
+$10.2M
Cap. Flow %
6.57%
Top 10 Hldgs %
70.21%
Holding
70
New
6
Increased
8
Reduced
6
Closed
3

Top Buys

Rank Stock Value
1
ELUT icon
Elutia
ELUT
+$8.01M
2
INBX
Inhibrx, Inc. Common Stock
INBX
+$1.6M
3
BDSX icon
Biodesix
BDSX
+$965K
4
TSVT
2seventy bio
TSVT
+$873K
5
NBIX icon
Neurocrine Biosciences
NBIX
+$828K

Top Sells

Rank Stock Value
1
XLRN
Acceleron Pharma
XLRN
+$1.84M
2
BMY icon
Bristol-Myers Squibb
BMY
+$1.76M
3
BLUE
bluebird bio
BLUE
+$539K
4
BIOR
Biora Therapeutics, Inc. Common Stock
BIOR
+$410K
5
VNDA icon
Vanda Pharmaceuticals
VNDA
+$349K

Sector Composition

Rank Sector Weight
1 Healthcare 96.09%
2 Energy 2.08%
3 Consumer Staples 0.21%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BMY icon
1
Bristol-Myers Squibb
BMY
$124B
$47.8M 30.8%
766,106
-30,000
-4% -$1.76M
AXDX
2
DELISTED
Accelerate Diagnostics
AXDX
$11.7M 7.57%
225,239
– –
ELUT icon
3
Elutia
ELUT
$42M
$8.35M 5.39%
1,417,923
+1,367,923
+2,736% +$8.01M
QDEL icon
4
QuidelOrtho
QDEL
$1.19B
$8.06M 5.2%
59,684
– –
NBIX icon
5
Neurocrine Biosciences
NBIX
$17.2B
$7.6M 4.9%
89,200
+9,000
+11% +$828K
FHTX icon
6
Foghorn Therapeutics
FHTX
$305M
$7.18M 4.63%
314,143
– –
BDSX icon
7
Biodesix
BDSX
$209M
$6.63M 4.27%
62,638
+7,390
+13% +$965K
ACAD icon
8
Acadia Pharmaceuticals
ACAD
$4.38B
$4.65M 3%
199,400
– –
UTHR icon
9
United Therapeutics
UTHR
$22.7B
$3.89M 2.51%
18,000
– –
BIIB icon
10
Biogen
BIIB
$30.4B
$3.02M 1.95%
12,600
– –
ALBO
11
DELISTED
Albireo Pharma Inc
ALBO
$2.63M 1.7%
113,000
– –
MASI
12
DELISTED
Masimo
MASI
$2.34M 1.51%
8,000
– –
ARNA
13
DELISTED
Arena Pharmaceuticals Inc
ARNA
$2.04M 1.32%
22,000
– –
PRTA icon
14
Prothena Corp
PRTA
$453M
$1.99M 1.28%
40,247
– –
INBX
15
DELISTED
Inhibrx, Inc. Common Stock
INBX
$1.75M 1.13%
+40,000
New +$1.6M
CLR
16
DELISTED
CONTINENTAL RESOURCES INC.
CLR
$1.73M 1.11%
38,600
– –
BHVN
17
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$1.65M 1.07%
12,000
+2,000
+20% +$254K
KPTI icon
18
Karyopharm Therapeutics
KPTI
$216M
$1.58M 1.02%
16,400
– –
HROW icon
19
Harrow
HROW
$1.74B
$1.55M 1%
180,000
– –
IMGN
20
DELISTED
Immunogen Inc
IMGN
$1.41M 0.91%
190,000
– –
ETRN
21
DELISTED
Equitrans Midstream Corporation Common Stock
ETRN
$1.38M 0.89%
133,050
– –
NKTR icon
22
Nektar Therapeutics
NKTR
$2.31B
$1.35M 0.87%
6,667
+1,867
+39% +$405K
PTGX icon
23
Protagonist Therapeutics
PTGX
$9.06B
$1.3M 0.84%
38,000
– –
ARVN icon
24
Arvinas
ARVN
$517M
$1.23M 0.79%
15,000
– –
ALKS icon
25
Alkermes
ALKS
$8.79B
$1.16M 0.75%
50,000
– –
1
2 3

Similar funds

RWA
Resolute Wealth Advisor Findlay, Ohio $176M AUM
BAM
Boyar Asset Management New York $176M AUM 20.04% 1-Year Est. Return
TIM
Tevis Investment Management Plano, Texas $176M AUM 18.14% 1-Year Est. Return
TFCM
Taylor Frigon Capital Management Scottsdale, Arizona $176M AUM 24.25% 1-Year Est. Return
FPW
Flywheel Private Wealth Los Altos, California $176M AUM 26.12% 1-Year Est. Return
LWM
Lifetime Wealth Management Rockwall, Texas $176M AUM
PFA
Providence Financial Advisors Overland Park, Kansas $175M AUM
DAM
Draper Asset Management Smithtown, New York $176M AUM 37.45% 1-Year Est. Return

Birchview Capital's Q4 2021 Portfolio in Review

As of Q4 2021, Birchview Capital held 70 positions worth $155M, up 5.5% from $147M the previous quarter. Its ten largest holdings account for 70% of the portfolio.

Birchview Capital deployed $10.2M of net new capital in Q4 2021, opening 6 new positions and adding to 8 existing holdings. Its largest new stake was Inhibrx, Inc. Common Stock: 40,000 shares worth $1.75M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 96% a quarter earlier, followed by Energy and Consumer Staples.

On the sell side, the largest reduction was Bristol-Myers Squibb, an estimated $1.76M trimmed.

  • Birchview Capital's largest Q4 2021 buy was Inhibrx, Inc. Common Stock: 40,000 shares worth $1.75M.
  • Birchview Capital added most to Elutia in Q4 2021, an estimated $8.01M increase.
  • Birchview Capital's biggest Q4 2021 reduction was Bristol-Myers Squibb, cutting an estimated $1.76M.
  • Birchview Capital fully exited Acceleron Pharma in Q4 2021, selling an estimated $1.84M.
  • Birchview Capital's ten largest holdings make up 70% of its $155M portfolio in Q4 2021.
  • Birchview Capital opened 6 new positions and closed 3 in Q4 2021.
  • Birchview Capital's portfolio value rose 5.5% quarter-over-quarter to $155M.

Based on Birchview Capital's 13F filing for Q4 2021, filed 14 Feb 2022.